Fawaz Faisal, MD
Sleep Medicine · Burbank, CANPI 1487679361
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 461 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,048 and has fallen 68.9% since, to $947 in 2025.
Across 461 payments — averaging $23.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$1K
- Livanova USA, Inc.$810
- UCB, Inc.$797
- Biogen$578
- Inspire Medical Systems, Inc.$443
- plus $6K from 46 others
What the payments were for
- Speaking & faculty fees$1111%
- Food & beverage$10,70798%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$494
- INBRIJA$247
- AUSTEDO$247
- Inspire$215
- CARDIOFORM Septal Occluder$179
- UBRELVY$125
- XCOPRI$123
- AIMOVIG$109
- Superion ISS$107
How this compares
$10,908 in reported general payments places this provider in the 85th percentile of 200 sleep medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 27 | $462,270 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $182,043 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 23 | $173,753 |
| CopaxoneGlatiramer Acetate | 28 | $157,408 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $130,283 |
| Kesimpta PenOfatumumab | 14 | $119,234 |
| AmpyraDalfampridine | 13 | $55,805 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $30,675 |
| AptiomEslicarbazepine Acetate | 12 | $29,305 |
| Lacosamide | 67 | $25,060 |
| BotoxOnabotulinumtoxina | 16 | $20,490 |
| Nurtec OdtRimegepant Sulfate | 12 | $16,329 |
| TopamaxTopiramate | 12 | $15,966 |
| Memantine Hcl | 515 | $10,535 |
| Levetiracetam | 218 | $9,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Dilantin | $81 | $480,99067 claims |
| CSL BehringPrivigen | $17 | $182,04314 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $409 | $157,40828 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $97 | $130,28313 claims |
| Acorda Therapeutics, IncAmpyra | $358 | $55,80513 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $219 | $29,30512 claims |
| AbbVieBotox | $1,439 | $20,49016 claims |
| MerckBelsomra | $38 | $4,85611 claims |
| Amneal Pharmaceuticals LLCRytary | $57 | $4,71512 claims |
| Upsher-smith Laboratories LLCTopiramate | $83 | $1,45356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 200 sleep medicine providers in California.
Other sleep medicine in Burbank
- Lisa ShivesSan Diego$1.4M
- Haramandeep SinghSan Ramon$1.1M
- Atul MalhotraSan Diego$771K
- Logan SchneiderStanford$506K
- Tony MasriLos Gatos$327K
- Sam KashaniSanta Monica$221K
- Emmanuel MignotStanford$135K
- Jerome HesterPalo Alto$74K
- Mark BuchfuhrerDowney$70K
- Clete KushidaStanford$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.